Clinical Trial Update: Phase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral Candidiasis [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2B dose-ranging study evaluating PAC113 mouthrinse for oral candidiasis in HIV-seropositive individuals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oral Candidiasis

Drugs mentioned

• PAC113 Mouthrinse (PAC113)

Snippet

Sponsor: Pacgen Biopharmaceuticals Corporation | Conditions: Oral Candidiasis | Phase 2 | Status: COMPLETED